- Name: Lu Zhen-hai
- Title: Chief Surgeon, Attending Doctor
- Email: luzhh@sysucc.org.cn
- Phone:
Dr. Lu Zhenhai specializes in surgical treatment of colorectal cancer, particularly laparoscopic minimally invasive treatment of colorectal tumors and comprehensive treatment of colorectal cancer. His expertise includes early diagnosis, staging, treatment, and prognosis research of colorectal cancer, transformation research of colorectal cancer liver metastasis, as well as comprehensive treatment and multidisciplinary treatment of colorectal cancer. He also focuses on the comprehensive treatment of locally advanced rectal cancer, including the selection of neoadjuvant treatment regimens, surgical treatment, and postoperative adjuvant treatment. In addition, Dr. Lu conducts basic and clinical research on hereditary colorectal cancer and clinical research on gastrointestinal stromal tumors.
Colorectal Cancer Liver Metastasis; Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
In 2007, Dr. Lu Zhenhai received his Doctor of Medicine degree from Sun Yat-sen University Cancer Center. He has served as a visiting scholar at the Southern Health and Peter MacCallum Cancer Centre, Monash University, and Queen Mary Hospital, the University of Hong Kong.
1. Zhang R, Wang F, Jiang X, Wang H, Zhang W, Zeng Z, Gao Y, Wu X, Chen G, Li L, Ding P, Lu S, Zhang J, Liu M, Wang Q, Xiao W, Pan Z, Wan D, Lu ZH. Short-Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. MedComm (2020). 2025 Jul 23;6(8):e70222. doi: 10.1002/mco2.70222. PMID: 40703195; PMCID: PMC12284437.
2. Zeng Z, Zhou J, Zhang W, Peng J, Li Y, Jin-Si-Han EE, Wang H, Lian S, Feng C, Xie C, Pan Z, Lu Z. Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR/MSI-H colorectal cancer. Front Immunol. 2025 May 30;16:1589869. doi: 10.3389/fimmu.2025.1589869. PMID: 40519904; PMCID: PMC12162661.
3. Li Y, Zhang W, Du J, Hu J, Hu R, Zeng Z, Jin-Si-Han EE, Lian S, Wang H, Li Y, Pan Z, Feng C, Zhang X, Lu Z. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Target Oncol. 2024 Jul;19(4):601-610. doi: 10.1007/s11523-024-01064-x. Epub 2024 Apr 30. Erratum in: Target Oncol. 2024 Jul;19(4):663. doi: 10.1007/s11523-024-01077-6. PMID: 38691294.